You are here
Articles
Posted on Thursday, November 8, 2007 - 10:05am
Please use this template as a basis (you can change it if you need to) for contacting your MP and making them aware of the situation regarding the proposed NICE appraisal for both Dasatinib and Nilotinib. It is crucial...
Posted on Wednesday, November 7, 2007 - 7:51pm
NCCN 2nd Annual Congress: Hematologic Malignancies - Update on Primary Therapy, Second-Line Therapy, and New Agents for Chronic Myelogenous Leukemia (Slides with Audio) CME/CE
Jerald P. Radich, MD
Posted on Monday, October 8, 2007 - 1:12pm
Please click on the link below to download a list of the centres that are open and recruiting.
Posted on Saturday, September 29, 2007 - 1:38pm
On 20 September 2007 the CHMP
(Committee for Medicinal Products for Human Use)
of the EMEA
(European Medicines Evaluation Agency) adopted a positive opinion towards Tasigna and recommended to grant a marketing...
Posted on Saturday, September 29, 2007 - 1:34pm
" Bristol-Myers Squibb is pleased about the approval of the 100mg once-daily stating dose of Sprycel for chronic phase patients..... The clinical data on the new starting dose demonstrate improved patient tolerability...
Posted on Thursday, September 13, 2007 - 5:37pm
The Health-EU Portal started issuing last week a multilingual newsletter, which aims to better inform European citizens on what is going on in the field of health at European and international level.
Posted on Thursday, September 13, 2007 - 2:25pm
Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy;...
Posted on Wednesday, May 9, 2007 - 2:03pm
Dasatinib (Sprycel) is accepted for restricted use for the treatment of adults with chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate...
Posted on Wednesday, April 25, 2007 - 1:54pm
Interesting article on mechanisms of resistance Imatinib more....
Posted on Wednesday, April 25, 2007 - 1:49pm
The current recommended first line therapy for newly diagnosed patients with CML is IM. However, despite the impressive responses achieved in the majority of patients, problems remain...
Posted on Sunday, December 10, 2006 - 6:47pm
Summary perspective of the 5th Annual CML Conference in Manchester on 6th/7th October
Firstly, it is worth note that having attended the last 3 of these conferences, we feel that there has been a continual improvement...
Posted on Monday, September 25, 2006 - 7:11am
Every EU citizen should fully understand the importance of this document because one in three of us will contract cancer over our lifetime and one in four of us will die from it. Cancer is a disease type that will...
Posted on Tuesday, September 19, 2006 - 4:19pm
A race against time... Patients' clamour for Gleevec began in spring 1999, as soon as the results of the first tests on CML patients spread. Thanks to the Internet they were aware of the drug from its early stages.
Posted on Saturday, September 9, 2006 - 3:45am
<IMG class="topleft" src="http://www.cmlsupport.org.uk/gfx/llambook.jpg" alt="image of book"></IMG>A practical...
![http://www.cmlsupport.org.uk/gfx/llambook.jpg"](http://www.cmlsupport.org.uk/gfx/llambook.jpg"){kind=link}
Posted on Saturday, July 22, 2006 - 4:14am
(CML) is a form of chronic leukemia characterized by increased production of myeloid cells in the bone marrow. It is a type of myeloproliferative disease...
- ‹ previous
- 29 of 29